Madrigal's Trading Volume Surges 193.71% to 1.84 Billion, Ranks 461st in Daily Market

On April 16, 2025, Madrigal's trading volume reached 1.84 billion, marking a significant increase of 193.71% compared to the previous day. This surge placed Madrigal at the 461st position in the daily stock market rankings. However, the stock price of Madrigal (MDGL) has been on a downward trend, falling by 4.15% over the past two days, with a cumulative decline of 4.51%.

Madrigal Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to acquire Resverlogix Corp. This acquisition is expected to enhance Madrigal's pipeline and strengthen its position in the cardiovascular disease market. The deal is subject to customary closing conditions and is anticipated to close in the third quarter of 2025.

Madrigal Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for resmetirom. The FDA has requested additional data to support the efficacy and safety of the drug. Madrigal plans to work closely with the FDA to address the concerns and resubmit the NDA as soon as possible.

Madrigal Pharmaceuticals, Inc. has announced that it will present new data on resmetirom at the American Heart Association's Scientific Sessions 2025. The presentation will include results from the Phase 3 MAESTRO-1 trial, which evaluated the efficacy and safety of resmetirom in patients with non-alcoholic steatohepatitis (NASH). The data is expected to provide further insights into the potential of resmetirom as a treatment for NASH.